EMEA-001798-PIP02-16-M01 - paediatric investigation plan
Enasidenib
PIPHuman
Bristol-Myers Squibb Pharma EEIG
tel. +44 1423 53 3610
E-mail : medical.information@bms.com
P/0456/2022: EMA decision of 28 October 2022 on the acceptance of a modification of an agreed paediatric investigation plan for enasidenib (EMEA- 001798-PIP02-16-M01)